Predicción del retraso en la eliminación de metotrexato mediante métodos bayesianos

Aquerreta González, I; Aldaz Pastor, A; Martínez Callejo, V; Giráldez Deiró, J; Sierrasesúmaga Ariznavarreta, L.
Farm. hosp ; 26(2): 90-95, mar. 2002. tab, graf
Artículo en Es | IBECS (España) | ID: ibc-17834

Documentos relacionados

  1. Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review.
  2. Delayed methotrexate elimination in a patient with primary central nervous system lymphoma: A case report.
  3. Risk factors associated with delayed methotrexate clearance and increased toxicity in pediatric patients with osteosarcoma.
  4. Delayed Methotrexate Elimination after Administration of a Medium Dose of Methotrexate in a Patient with Genetic Variants Associated with Methotrexate Clearance.
  5. Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma.
  6. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: a prognostic value?
  7. Methotrexate Elimination When Coadministered With Levetiracetam.
  8. Plasma Distribution of Methotrexate and Its Polyglutamates in Pediatric Acute Lymphoblastic Leukemia: Preliminary Insights.
  9. Calcium Channel Blockers Possibly Delay the Elimination of Plasma Methotrexate in Patients Receiving High-Dose Methotrexate Therapy.
  10. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.